News/ News/ R&D SparingVision to buy GAMUT and potential Luxturna eye gene therapy competitor Richard Staines SparingVision 0 Comment French genomic medicines firm SparingVision has agreed to buy GAMUT Therapeutics, a biotech specialising in gene therapies for Share X SparingVision to buy GAMUT and potential Luxturna eye gene therapy competitor https://pharmaphorum.com/news/sparingvision-to-buy-gamut-and-potential-luxturna-gene-therapy-competitor/
News/ News/ R&D SparingVision raises €44.5m for retinitis pigmentosa gene therapy Richard Staines Funding, ophthalmology, Oxford Biomedica, R&D, Sanofi, SparingVision 0 Comment French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share X SparingVision raises €44.5m for retinitis pigmentosa gene therapy https://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
